Bupropion and naltrexone and Camrese extended-cycle
Determining the interaction of Bupropion and naltrexone and Camrese extended-cycle and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: bupropion / naltrexone
Brand name: Contrave
Synonyms: Naltrexone and Bupropion
Generic Name: ethinyl estradiol / levonorgestrel
Brand name: Amethia, Amethia Lo, Camrese, Camrese Lo, Daysee, Introvale, Jolessa, LoSeasonique, Quartette, Quasense, Seasonale, Seasonique, Afirmelle, Altavera, Amethyst, Ashlyna, Aubra, Aubra EQ, Aviane, Ayuna, Balcoltra, Chateal, Chateal EQ, Delyla, Enpresse-28, FaLessa, Falmina, Fayosim, Kurvelo, Larissia, Lessina, Levonest, Levora 015/30, Lillow, Lutera, Marlissa, Myzilra, Orsythia, Portia-28, Rivelsa, Setlakin, Simpesse, Sronyx, Trivora, Vienva, Alesse, Enpresse, Levlen, Levora, Lybrel, Nordette, Portia, Tri-Levlen, Triphasil-21, Triphasil-28, Trivora-28, Preven EC, Triphasil
Synonyms: Camrese (extended-cycle), Camrese
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Bupropion and naltrexone-Camrese Lo
- Bupropion and naltrexone-Camrese Lo extended-cycle
- Bupropion and naltrexone-Canagliflozin
- Bupropion and naltrexone-Canagliflozin and metformin
- Bupropion and naltrexone-Canagliflozin and Metformin Extended-Release Tablets
- Bupropion and naltrexone-Canagliflozin and Metformin Tablets
- Camrese extended-cycle-Bupropion Extended-Release Tablets
- Camrese extended-cycle-Bupropion Hydrochloride
- Camrese extended-cycle-Bupropion SR Tablets
- Camrese extended-cycle-Bupropion Sustained-Release Tablets (Smoking Deterrent)
- Camrese extended-cycle-Bupropion Tablets
- Camrese extended-cycle-Bupropion Tablets and Sustained-Release Tablets